ABSTRACT
BACKGROUND Tourette syndrome (TS) is caused by multiple genetic and environmental factors. Yet, little is known about the interplay of these factors in the occurrence of tics in the general population.
METHODS Using logistic regression, we investigated whether polygenic risk score (PRS) of TS and pregnancy-related environmental factors together enhance the explained variance of tic occurrence (as opposed to separate analysis) in the Avon Longitudinal Study of Parents and Children. We included a cumulative adverse pregnancy risk score, maternal anxiety and depression, and maternal smoking and alcohol use during pregnancy. We investigated possible independent (i.e. additive) genetic and environmental effects, gene-environment correlations (rGE), gene-environment interactions (G x E), and mediation effects in explaining tic presence.
RESULTS Models that contained the PRS and the cumulative adverse pregnancy risk score, maternal anxiety, or maternal depression (but not maternal smoking and alcohol use) explained significantly more variance of tic presence compared to models including only the PRS, pointing to additive effects. Furthermore, we found that maternal anxiety, depression, and smoking were mediated by the cumulative adverse pregnancy risk score, and were thus all indirectly associated with tics through pregnancy complications. We did not find rGE or G x E.
CONCLUSIONS We found evidence for both direct and indirect associations of environmental risk factors in relation to tics in the general population. Combining PRS and environmental risk factors improve our understanding of tics compared to considering these factors in isolation, suggesting both additive and mediation effects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by National Institute of Mental Health (NIMH) grant R01MH092293 (to GAH and JAT) and NJCTS (New Jersey Center for Tourette Syndrome and Associated Disorders; to GAH and JAT). This work was also supported by grants from the Judah Foundation, the Tourette Association of America, National Institute of Health (NIH) Grants NS40024, NS016648, MH079489, MH073250, the American Recovery and Re-investment Act (ARRA) Grants NS040024-07S1, NS16648-29S1, NS040024-09S1, MH092289; MH092290; MH092291; MH092292; R01MH092293; MH092513; MH092516; MH092520; MH071507; MH079489; MH079487; MH079488; and MH079494. The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and Mohamed Abdulkadir will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the ALSPAC Ethics and Law Committee. All participants provided written informed consent or assent. Consent for biological samples has been collected in accordance with the Human Tissue Act (2004). Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The study website contains details of available data through a fully searchable data dictionary: http://www.bristol.ac.uk/alspac/researchers/our-data/.
